Atopic dermatitis (AD), also referred to as eczema, is a chronic inflammatory skin disorder affecting more than 102.8 million children and 101.3 million adults worldwide. 2 AD is characterized by ...

Eliminating “problematic” foods or ingredients from the diet is not a sensible measure to apply across all patients with atopic dermatitis (AD), although it may be beneficial for a subset of ...

Galderma has shared positive two-year data for its monoclonal antibody Nemluvio (nemolizumab) in moderate-to-severe atopic dermatitis. The ARCADIA long-term extension (LTE) study has been evaluating ...

The AJMC® Atopic Dermatitis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin condition that typically develops in early childhood.

Improvement in Atopic Dermatitis Signs and Symptoms with Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.15% or 0.05%: Results from the 52-Week Phase 3 INTEGUMENT-OLE Trial in Patients ...

Sanofi and Regeneron have shared positive results from a phase 4 study of their monoclonal antibody Dupixent (dupilumab) in atopic dermatitis patients with skin of colour. Data from the open-label ...

Zoryve cream helped 63.1% of children aged 2–5 reach vIGA-AD 0/1 after 56 weeks. Only 2.5% of kids aged 2–5 experienced treatment-related side effects in the study. Market-moving news hits ...

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall disease severity, the primary endpoint, in more ...

TOPLINE: Treating atopic dermatitis (AD) with dupilumab vs other systemic agents increased the risk of developing psoriasis over 3 years, a cohort study found. METHODOLOGY: Addressing ...

Patients with atopic dermatitis (AD) treated with dupilumab may face a slightly elevated risk of developing psoriasis, with new study data showing a cumulative 3-year incidence of 2.86% compared ...

Video: What to Know About Treatment of Atopic Dermatitis Based on the 2024 AAD Guidelines —Megan Rogge, MD, associate professor of dermatology at UT Health in Houston, shares her opinion on the ...

The Phase 1b trial is designed to evaluate the safety, tolerability, pharmacokinetics, target engagement, and early signs of efficacy of ENV-294 in patients with moderate to severe atopic dermatitis.